The incidence of metabolic syndrome is rapidly increasing worldwide, and adequate animal
models are crucial for studies on its pathogenesis and therapy. In the search of an
adequate experimental model to simulate human metabolic syndrome, the present study was
performed to examine the pharmacological response of
WBN/Kob-Leprfa (WBKDF) rats supplemented with a
fructose-rich diet (FRD) to liraglutide, a GLP-1 receptor agonist. Male WBKDF rats fed FRD
at 7 weeks of age were divided into 3 groups, and administered liraglutide (75, 300
µg/kg subcutaneously) or saline (control group), once daily for 4 weeks. All
rats in the control group became overweight, and developed hyperglycemia, hypertension and
dyslipidemia as they aged. The rats given liraglutide exhibited a dose-dependent reduction
in body weight, visceral fat content and food intake compared with control rats. In
addition, liraglutide suppressed the development of hyperglycemia, hypertension and
dyslipidemia. An intravenous glucose tolerance test revealed that liraglutide improved
glucose tolerance, insulin secretion and insulin resistance. On histological examination,
decreased hepatic fatty degeneration was observed in the liraglutide groups. The present
study demonstrated that liraglutide protected against obesity, hyperglycemia,
hypertension, dyslipidemia, and hepatic steatosis in WBKDF rats fed FRD, suggesting that
WBKDF rats fed FRD may be a useful model to investigate the etiology of human metabolic
syndrome.